Myocardial protection by nitrite

Cardiovascular Research

Volumn 83, Issue 2, 2009, Pages 195-203

  Calvert, John W ^a   Lefer, David J ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute myocardial infarction; Cardioprotection; Myocardial ischaemia; Nitric oxide; Nitrite

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC OXIDE; NITRITE; PHOSPHODIESTERASE INHIBITOR; SODIUM NITRATE;

ACUTE HEART INFARCTION; ARTERY DISEASE; BRAIN VASOSPASM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL PROTECTION; CHEMOLUMINESCENCE; CLINICAL EVALUATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; ELECTRON SPIN RESONANCE; ENDOCRINE FUNCTION; EVIDENCE BASED PRACTICE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HOMEOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REPERFUSION INJURY; REVIEW; SICKLE CELL ANEMIA; STROKE; SYNTHESIS;

ANIMALS; CYTOPROTECTION; HOMEOSTASIS; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NITRIC OXIDE; NITRITES; RISK FACTORS; TREATMENT OUTCOME;

EID: 67650242010     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp079     Document Type: Review

References (113)

1. Gladwin MT, Raat NJ, Shiva S, Dezfulian C, Hogg N, Kim-Shapiro DB et al. Nitrite as a vascular endocrine nitric oxide reservoir that contributes to hypoxic signaling, cytoprotection, and vasodilation. Am J Physiol Heart Circ Physiol 2006;291:H2026-H2035.
2. Gladwin MT, Schechter AN, Kim-Shapiro DB, Patel RP, Hogg N, Shiva S et al. The emerging biology of the nitrite anion. Nat Chem Biol 2005; 1:308-314.
3. Dezfulian C, Raat N, Shiva S, Gladwin MT. Role of the anion nitrite in ischemia-reperfusion cytoprotection and therapeutics. Cardiovasc Res 2007;75:327-338.
4. Lefer DJ. Nitrite therapy for protection against ischemia-reperfusion injury. Am J Physiol Renal Physiol 2006;290:F777-F778.
5. Lundberg JO, Weitzberg E, Gladwin MT. The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov 2008;7:156-167.
6. Sinha SS, Shiva S, Gladwin MT. Myocardial protection by nitrite: evidence that this reperfusion therapeutic will not be lost in translation. Trends Cardiovasc Med 2008;18:163-172.
7. Szabo C. Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov 2007;6:917-935.
8. Murad F. Shattuck Lecture. Nitric oxide and cyclic GMP in cell signaling and drug development. N Engl J Med 2006;355:2003-2011.
9. Ignarro LJ. Nitric oxide: a unique endogenous signaling molecule in vascular biology. Biosci Rep 1999;19:51-71.
10. Michel T, Feron O. Nitric oxide synthases: which, where, how, and why? J Clin Invest 1997;100:2146-2152.
11. Loscalzo J, Welch G. Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis 1995;38:87-104.
12. Sharp BR, Jones SP, Rimmer DM, Lefer DJ. Differential response to myo- cardial reperfusion injury in eNOS-deficient mice. Am J Physiol Heart Circ Physiol 2002;282:H2422-H2426.
13. Jones SP, Girod WG, Palazzo AJ, Granger DN, Grisham MB, Jourd'Heuil D et al. Myocardial ischemia-reperfusion injury is exacerbated in absence of endothelial cell nitric oxide synthase. Am J Physiol 1999;276:H1567-H1573.
14. Elrod JW, Greer JJ, Bryan NS, Langston W, Szot JF, Gebregzlabher H et al. Cardiomyocyte-specific overexpression of NO synthase-3 protects against myocardial ischemia-reperfusion injury. Arterioscler Thromb Vasc Biol 2006;26:1517-1523.
15. Jones SP, Greer JJ, Kakkar AK, Ware PD, Turnage RH, Hicks M et al. Endo- thelial nitric oxide synthase overexpression attenuates myocardial reperfusion injury. Am J Physiol Heart Circ Physiol 2004;286:H276- H282.
16. Pabla R, Buda AJ, Flynn DM, Blesse SA, Shin AM, Curtis MJ et al. Nitric oxide attenuates neutrophil-mediated myocardial contractile dysfunction after ischemia and reperfusion. Circ Res 1996;78:65-72.
17. Siegfried MR, Carey C, Ma XL, Lefer AM. Beneficial effects of SPM-5185, a cysteine-containing NO donor in myocardial ischemia-reperfusion. Am J Physiol 1992; 263:H771-H777.
18. Hataishi R, Rodrigues AC, Neilan TG, Morgan JG, Buys E, Shiva S et al. Inhaled nitric oxide decreases infarction size and improves left ventricular function in a murine model of myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2006;291:H379-H384.
19. Bolli R. Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. J Mol Cell Cardiol 2001;33:1897-1918.
20. Lefer DJ. Myocardial protective actions of nitric oxide donors after myo- cardial ischemia and reperfusion. New Horiz 1995;3:105-112.
21. Johnson G III, Tsao PS, Lefer AM. Cardioprotective effects of authentic nitric oxide in myocardial ischemia with reperfusion. Crit Care Med 1991;19:244-252.
22. Loke KE, Laycock SK, Mital S, Wolin MS, Bernstein R, Oz M et al. Nitric oxide modulates mitochondrial respiration in failing human heart. Circulation 1999;100:1291-1297.
23. Thomas DD, Liu X, Kantrow SP, Lancaster JR Jr. The biological lifetime of nitric oxide: implications for the perivascular dynamics of NO and O2.Proc Natl Acad Sci USA 2001;98:355-360.
24. Ma XL, Weyrich AS, Lefer DJ, Lefer AM. Diminished basal nitric oxide release after myocardial ischemia and reperfusion promotes neutrophil adherence to coronary endothelium. Circ Res 1993;72:403-412.
25. Palazzo AJ, Jones SP, Girod WG, Anderson DC, Granger DN, Lefer DJ. Myocardial ischemia-reperfusion injury in CD18- and ICAM-1-deficient mice. Am J Physiol 1998;275:H2300-H2307.
26. Walter U, Gambaryan S. Roles of cGMP/cGMP-dependent protein kinase in platelet activation. Blood 2004;104:2609.
27. Calvert JW, Lefer DJ. Statin therapy and myocardial no-reflow. Br J Pharmacol 2006;149:229-231.
28. Li J, Bombeck CA, Yang S, Kim YM, Billiar TR. Nitric oxide suppresses apoptosis via interrupting caspase activation and mitochondrial dysfunction in cultured hepatocytes. J Biol Chem 1999;274:17325-17333.
29. Kim YM, Talanian RV, Billiar TR. Nitric oxide inhibits apoptosis by preventing increases in caspase-3-like activity via two distinct mechanisms. J Biol Chem 1997;272:31138-31148.
30. Xuan YT, Guo Y, Zhu Y, Wang OL, Rokosh G, Bolli R. Endothelial nitric oxide synthase plays an obligatory role in the late phase of ischemic preconditioning by activating the protein kinase C epsilon p44/42 mitogen-activated protein kinase pSer-signal transducers and activators of transcription1/3 pathway. Circulation 2007;116:535-544.
31. Bolli R, Dawn B, Xuan YT. Role of the JAK-STAT pathway in protection against myocardial ischemia/reperfusion injury. Trends Cardiovasc Med 2003;13:72-79.
32. Smart N, Mojet MH, Latchman DS, Marber MS, Duchen MR, Heads RJ. IL-6 induces PI 3-kinase and nitric oxide-dependent protection and preserves mitochondrial function in cardiomyocytes. Cardiovasc Res 2006;69:164-177.
33. Rakhit RD, Mojet MH, Marber MS, Duchen MR. Mitochondria as targets for nitric oxide-induced protection during simulated ischemia and reox- ygenation in isolated neonatal cardiomyocytes. Circulation 2001;103:2617-2623.
34. Hu H, Chiamvimonvat N, Yamagishi T, Marban E. Direct inhibition of expressed cardiac L-type Ca2+ channels by S-nitrosothiol nitric oxide donors. Circ Res 1997;81:742-752.
35. Sun J, Picht E, Ginsburg KS, Bers DM, Steenbergen C, Murphy E. Hyper- contractile female hearts exhibit increased S-nitrosylation of the L-type Ca2+ channel alphal subunit and reduced ischemia/reperfusion injury. Circ Res 2006;98:403-411.
36. Rickover O, Zinman T, Kaplan D, Shainberg A. Exogenous nitric oxide triggers classic ischemic preconditioning by preventing intracellular Ca2+ overload in cardiomyocytes. Cell Calcium 2008;43:324-333.
37. Li Q, Guo Y, Xuan YT, Lowenstein CJ, Stevenson SC, Prabhu SD et al. Gene therapy with inducible nitric oxide synthase protects against myocardial infarction via a cyclooxygenase-2-dependent mechanism. Circ Res 2003;92:741-748.
38. Costa AD, Garlid KD, West IC, Lincoln TM, Downey JM, Cohen MV et al. Protein kinase G transmits the cardioprotective signal from cytosol to mitochondria. Circ Res 2005;97:329-336.
39. Burwell LS, Nadtochiy SM, Tompkins AJ, Young S, Brookes PS. Direct evidence for S-nitrosation of mitochondrial complex I. Biochem J 2006; 394:627-634.
40. Murphy E, Steenbergen C. Cardioprotection in females: a role for nitric oxide and altered gene expression. Heart Fail Rev 2007;12:293-300.
41. Becker BF, Heindl B, Kupatt C, Zahler S. Endothelial function and hemos- tasis. ZKardiol 2000;89:160-167.
42. Lefer AM, Campbell B, Shin YK, Scalia R, Hayward R, Lefer DJ. Simvastatin preserves the ischemic-reperfused myocardium in normocholester- olemic rat hearts. Circulation 1999;100:178-184.
43. Lefer DJ, Scalia R, Jones SP, Sharp BR, Hoffmeyer MR, Farvid AR et al. HMG-CoA reductase inhibition protects the diabetic myocardium from ischemia-reperfusion injury. FASEB J 2001;15:1454-1456.
44. Scalia R, Gooszen ME, Jones SP, Hoffmeyer M, Rimmer DM III, Trocha SD et al. Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein E-deficient mice. Circulation 2001;103:2598-2603.
45. Elrod JW, Greer JJ, Lefer DJ. Sildenafil-mediated acute cardioprotection is independent of the NO/cGMP pathway. Am J Physiol Heart Circ Physiol 2007;292:H342-H347.
46. Kukreja R, Salloum F, Xi L. Anti-ischemic effects of sildenafil, vardenafil and tadalafil in heart. Int J Impot Res 2007;19:226- 227.
47. Kukreja RC, Ockaili R, Salloum F, Xi L. Sildenafil-induced cardioprotection in rabbits. Cardiovasc Res 2003;60:700-701. author reply 702-703.
48. Webb A, Bond R, McLean P, Uppal R, Benjamin N, Ahluwalia A. Reduction of nitrite to nitric oxide during ischemia protects against myocardial ischemia-reperfusion damage. Proc Natl Acad Sci USA 2004;101: 13683-13688.
49. Kelm M. Nitric oxide metabolism and breakdown. Biochim Biophys Acta 1999;1411:273-289.
50. Lauer T, Preik M, Rassaf T, Strauer BE, Deussen A, Feelisch M et al. Plasma nitrite rather than nitrate reflects regional endothelial nitric oxide synthase activity but lacks intrinsic vasodilator action. Proc Natl Acad Sci USA 2001;98:12814-12819.
51. Bryan NS, Fernandez BO, Bauer SM, Garcia-Saura MF, Milsom AB, Rassaf T et al. Nitrite is a signaling molecule and regulator of gene expression in mammalian tissues. Nat Chem Biol 2005;1:290-297.
52. Duranski MR, Greer JJ, Dejam A, Jaganmohan S, Hogg N, Langston W et al. Cytoprotective effects of nitrite during in vivo ischemia-reperfusion of the heart and liver. J Clin Invest 2005;115:1232-1240.
53. Lundberg JO, Govoni M. Inorganic nitrate is a possible source for systemic generation of nitric oxide. Free Radic Biol Med 2004;37:395-400.
54. Lundberg JO, Weitzberg E. NO generation from nitrite and its role in vascular control. Arterioscler Thromb Vasc Biol 2005;25:915-922.
55. Lundberg JO, Weitzberg E, Cole JA, Benjamin N. Nitrate, bacteria and human health. Nat Rev Microbiol 2004;2:593-602.
56. Furchgott RF. Endothelium-derived relaxing factor: discovery, early studies, and identification as nitric oxide. Biosci Rep 1999;19:235-251.
57. Johnson G III, Tsao PS, Mulloy D, Lefer AM. Cardioprotective effects of acidified sodium nitrite in myocardial ischemia with reperfusion.J Pharmacol Exp Ther 1990;252:35-41.
58. Bryan NS. Nitrite in nitric oxide biology: cause or consequence? A systems-based review. Free Radic Biol Med 2006;41:691 -701.
59. Zweier JL, Wang P, Samouilov A, Kuppusamy P. Enzyme-independent formation of nitric oxide in biological tissues. Nat Med 1995;1:804-809.
60. Bryan NS, Rassaf T, Maloney RE, Rodriguez CM, Saijo F, Rodriguez JR et al. Cellular targets and mechanisms of nitros(yl)ation: an insight into their nature and kinetics in vivo. Proc Natl Acad Sci USA 2004; 101:4308-4313.
61. Zweier JL, Samouilov A, Kuppusamy P. Non-enzymatic nitric oxide synthesis in biological systems. Biochim Biophys Acta 1999;1411:250-262.
62. Samouilov A, Kuppusamy P, Zweier JL. Evaluation of the magnitude and rate of nitric oxide production from nitrite in biological systems. Arch Biochem Biophys 1998;357:1-7.
63. Shiva S, Sack MN, Greer JJ, Duranski M, Ringwood LA, Burwell L et al. Nitrite augments tolerance to ischemia/reperfusion injury via the modulation of mitochondrial electron transfer. J Exp Med 2007;204:2089-2102.
64. Gonzalez FM, Shiva S, Vincent PS, Ringwood LA, Hsu LY, Hon YY et al. Nitrite anion provides potent cytoprotective and antiapoptotic effects as adjunctive therapy to reperfusion for acute myocardial infarction. Circulation 2008; 117:2986-2994.
65. Baker JE, Su J, Fu X, Hsu A, Gross GJ, Tweddell JS et al. Nitrite confers protection against myocardial infarction: role of xanthine oxidoreduc-tase, NADPH oxidase and K(ATP) channels. J Mol Cell Cardiol 2007;43:437-444.
66. Lu P, Liu F, Yao Z, Wang CY, Chen DD, Tian Y et al. Nitrite-derived nitric oxide by xanthine oxidoreductase protects the liver against ischemia-reperfusion injury. Hepatobiliary Pancreat Dis Int 2005;4:350-355.
67. Jung KH, Chu K, Ko SY, Lee ST, Sinn DI, Park DK et al. Early intravenous infusion of sodium nitrite protects brain against in vivo ischemia-reperfusion injury. Stroke 2006;37:2744-2750.
68. Tripatara P, Patel NS, Webb A, Rathod K, Lecomte FM, Mazzon E et al. Nitrite-derived nitric oxide protects the rat kidney against ischemia/ reperfusion injury in vivo: role for xanthine oxidoreductase. J Am Soc Nephrol 2007;18:570-580.
69. Pluta RM, Dejam A, Grimes G, Gladwin MT, Oldfield EH. Nitrite infusions to prevent delayed cerebral vasospasm in a primate model of subarach- noid hemorrhage. JAMA 2005;293:1477-1484.
70. Tsuchiya K, Kanematsu Y, Yoshizumi M, Ohnishi H, Kirima K, Izawa Y et al. Nitrite is an alternative source of NO in vivo. Am J Physiol Heart Circ Physiol 2005;288:H2163-H2170.
71. Walters CL, Casselden RJ, Taylor AM. Nitrite metabolism by skeletal muscle mitochondria in relation to haem pigments. Biochim Biophys Acta 1967;143:310-318.
72. Reutov VP, Sorokina EG. NO-synthase and nitrite-reductase components of nitric oxide cycle. Biochemistry (Mosc) 1998;63:874-884.
73. Kozlov AV, Staniek K, Nohl H. Nitrite reductase activity is a novel function of mammalian mitochondria. FEBS Lett 1999;454:127-130.
74. Cosby K, Partovi KS, Crawford JH, Patel RP, Reiter CD, Martyr S et al. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat Med 2003;9:1498-1505.
75. Li H, Samouilov A, Liu X, Zweier JL. Characterization of the effects of oxygen on xanthine oxidase-mediated nitric oxide formation. J Biol Chem 2004;279:16939-16946.
76. Alikulov ZA, L'Vov NP, Kretovich VL. [Nitrate nitrite reductase activity of milk xanthine oxidase]. Biokhimiia 1980;45:1714-1718.
77. Rassaf T, Flogel U, Drexhage C, Hendgen-Cotta U, Kelm M, Schrader J. Nitrite reductase function of deoxymyoglobin: oxygen sensor and regulator of cardiac energetics and function. Circ Res 2007;100:1749-1754.
78. Shiva S, Huang Z, Grubina R, Sun J, Ringwood LA, MacArthur PH et al. Deoxymyoglobin is a nitrite reductase that generates nitric oxide and regulates mitochondrial respiration. Circ Res 2007;100:654-661.
79. Brunori M. Nitric oxide moves myoglobin centre stage. Trends Biochem Sci 2001;26:209-210.
80. Kleinbongard P, Dejam A, Lauer T, Rassaf T, Schindler A, Picker O et al. Plasma nitrite reflects constitutive nitric oxide synthase activity in mammals. Free Radic Biol Med 2003;35:790-796.
81. Elrod JW, Calvert JW, Gundewar S, Bryan NS, Lefer DJ. Nitric oxide promotes distant organ protection: evidence for an endocrine role of nitric oxide. Proc Natl Acad Sci USA 2008;105:11430-11435.
82. Bryan NS, Calvert JW, Elrod JW, Gundewar S, Ji SY, Lefer DJ. Dietary nitrite supplementation protects against myocardial ischemia-reperfusion injury. Proc Natl Acad Sci USA 2007;104:19144.
83. Bryan NS, Calvert JW, Gundewar S, Lefer DJ. Dietary nitrite restores NO homeostasis and is cardioprotective in endothelial nitric oxide synthase- deficient mice. Free Radic Biol Med 2008;45:468-474.
84. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001;104:2673-2678.
85. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000;87:840-844.
86. Harrison DG. Endothelial dysfunction in the coronary microcirculation: a new clinical entity or an experimental finding? J Clin Invest 1993;91:1-2.
87. Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 2001;88:E14-E22.
88. Lefer AM, Lefer DJ. Pharmacology of the endothelium in ischemia- reperfusion and circulatory shock. Annu Rev Pharmacol Toxicol 1993;33:71-90.
89. Lefer AM, Ma XL, Weyrich A, Lefer DJ. Endothelial dysfunction and neu- trophil adherence as critical events in the development of reperfusion injury. Agents Actions Suppl 1993;41:127-135.
90. Lefer DJ, Lefer AM. Nitric oxide homeostasis control as therapy for cardiovascular diseases. Cardiovasc Res 1993;27:2282.
91. Kleinbongard P, Dejam A, Lauer T, Jax T, Kerber S, Gharini P et al. Plasma nitrite concentrations reflect the degree of endothelial dysfunction in humans. Free Radic Biol Med 2006;40:295-302.
92. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium- derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987;84:9265-9269.
93. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327:524-526.
94. Liu X, Miller MJ, Joshi MS, Sadowska-Krowicka H, Clark DA, Lancaster JR Jr. Diffusion-limited reaction of free nitric oxide with erythrocytes. J Biol Chem 1998;273:18709-18713.
95. Kelm M, Schrader J. Control of coronary vascular tone by nitric oxide.Circ Res 1990;66:1561-1575.
96. Dudzinski DM, Igarashi J, Greif D, Michel T. The regulation and pharmacology of endothelial nitric oxide synthase. Annu Rev Pharmacol Toxicol 2006;46:235-276.
97. Sessa WC. eNOS at a glance. J Cell Sci 2004;117:2427-2429.
98. Troncy E, Francoeur M, Salazkin I, Yang F, Charbonneau M, Leclerc G et al. Extra-pulmonary effects of inhaled nitric oxide in swine with and without phenylephrine. Br J Anaesth 1997;79:631-640.
99. Quezado ZM, Natanson C, Karzai W, Danner RL, Koev CA, Fitz Y et al. Cardiopulmonary effects of inhaled nitric oxide in normal dogs and during E. coli pneumonia and sepsis. J Appl Physiol 1998;84:107- 115.
100. Takahashi Y, Kobayashi H, Tanaka N, Sato T, Takizawa N, Tomita T. Nitro- syl hemoglobin in blood of normoxic and hypoxic sheep during nitricoxide inhalation. Am J Physiol 1998;274:H349-H357.
101. Fox-Robichaud A, Payne D, Hasan SU, Ostrovsky L, Fairhead T, Reinhardt P et al. Inhaled NO as a viable antiadhesive therapy for ischemia/reperfusion injury of distal microvascular beds. J Clin Invest 1998;101:2497-2505.
102. Kubes P, Payne D, Grisham MB, Jourd-Heuil D, Fox-Robichaud A. Inhaled NO impacts vascular but not extravascular compartments in postis- chemic peripheral organs. Am J Physiol 1999;277:H676-H682.
103. Ng ES, Jourd'heuil D, McCord JM, Hernandez D, Yasui M, Knight D et al. Enhanced S-nitroso-albumin formation from inhaled NO during ischemia/reperfusion. Circ Res 2004;94:559-565.
104. Cannon RO III, Schechter AN, Panza JA, Ognibene FP, Pease-Fye ME, Waclawiw MA et al. Effects of inhaled nitric oxide on regional blood flow are consistent with intravascular nitric oxide delivery. J Clin Invest 2001;108:279-287.
105. Zuzak KJ, Schaeberle MD, Gladwin MT, Cannon RO III, Levin IW. Noninva- sive determination of spatially resolved and time-resolved tissue perfusion in humans during nitric oxide inhibition and inhalation by use of a visible-reflectance hyperspectral imaging technique. Circulation 2001;104:2905-2910.
106. Rassaf T, Preik M, Kleinbongard P, Lauer T, Heiss C, Strauer BE et al. Evidence for in vivo transport of bioactive nitric oxide in human plasma.J Clin Invest 2002;109:1241-1248.
107. Heiss C, Lauer T, Dejam A, Kleinbongard P, Hamada S, Rassaf T et al. Plasma nitroso compounds are decreased in patients with endothelial dysfunction. J Am Coll Cardiol 2006;47:573-579.
108. Hogg N, Broniowska KA, Novalija J, Kettenhofen NJ, Novalija E. Role or S-nitrosothiol transport in the cardioprotective effects of S- nitrosocysteine in rat hearts. Free Radic Biol Med 2007
109. Funai EF, Davidson A, Seligman SP, Finlay TH. S-nitrosohemoglobin in the fetal circulation may represent a cycle for blood pressure regulation. Biochem Biophys Res Commun 1997;239:875-877.
110. Stamler JS, Jaraki O, Osborne J, Simon DI, Keaney J, Vita J et al. Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc Natl Acad Sci USA 1992;89:7674-7677.
111. Wittenberg JB, Wittenberg BA. Myoglobin function reassessed. J Exp Biol 2003;206:2011-2020.
112. Flogel U, Godecke A, Klotz LO, Schrader J. Role of myoglobin in the antioxidant defense of the heart. Faseb J 2004;18:1156-1158.
113. Kumar D, Branch BG, Pattillo CB, Hood J, Thoma S, Simpson S et al. Chronic sodium nitrite therapy augments ischemia-induced angiogenesis and arteriogenesis. Proc Natl Acad Sci USA 2008;105:7540-7545.